Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
Abivax reported positive topline results from the ABTECT Maintenance Part 2 trial, showing that 37.2% of induction non-responders achieved clinical remission with continued 50 mg obefazimod treatment. Integrated safety data across 1,704 patient-years indicated malignancy rates consistent with expected background rates for ulcerative colitis, with no new safety signals emerging in the expanded dataset.
Key figures
- Drug Name
- obefazimod
- Phase Of Trial
- Phase 3
- Eair nmsc integrated all active
- 0.59
- Integrated patient years exposure
- 1704
- Eair malignancies integrated all active
- 0.35
- Clinical remisssion relapsers 25 to 50mg
- 45.5%
- Clinical remission induction non responders 50mg
- 37.2%
- Endoscopic remission induction non responders 50mg
- 34.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.